• MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.

Peer Exchange

Updates in the Management of Relapsing Multiple Sclerosis
EP. 1: 2017 Changes to the McDonald Criteria: Diagnosing Multiple Sclerosis
EP. 2: Use of MRI in Diagnosing Multiple Sclerosis
EP. 3: Misdiagnosis of Multiple Sclerosis
EP. 4: Cerebrospinal Fluid in Diagnosing Multiple Sclerosis
EP. 5: Challenges in Optimally Treating Multiple Sclerosis
EP. 6: QoL Issues in the Management of Multiple Sclerosis
EP. 7: Multiple Sclerosis Fatigue
EP. 8: TRIUMPHANT-MS Trial: Fatigue in MS
EP. 9: OPTIMUM Phase 3 Trial: Secondary End Point Effect on Fatigue
EP. 10: Strategies for Choosing Initial Therapy in MS
EP. 11: Anti-CD20 Monoclonal Antibodies for Treatment of RMS
EP. 12: Cladribine for Treatment of RMS
EP. 13: S1P Receptor Modulators for Treatment of RMS
EP. 14: Fumarates for Treatment of RMS
Advances in the Management of Acute Treatment of Migraine
EP. 1: Unmet Needs in the Management of Migraine
EP. 2: Acute Treatment of Migraine: Traditional Therapies
EP. 3: Evolution of Acute Treatment of Migraine
EP. 4: Acute Treatment of Migraine: Progress With Novel Medications
EP. 5: Use of 5-HT1F Agonists in Acute Treatment of Migraine
EP. 6: Safety of CGRP Receptor Antagonists vs 5-HT1F Agonists
EP. 7: Intranasal DHE in Acute Treatment of Migraine
EP. 8: Patient Selection of Novel Therapies for Migraine Treatment
EP. 9: Role of Neuromodulation for Acute Treatment of Migraine
EP. 10: Patient Selection for Neuromodulation Devices
EP. 11: Behavioral and Lifestyle Strategies for Migraine Management
Global Approaches to the Management of Relapsing Multiple Sclerosis
EP. 1: Diagnosis of Multiple Sclerosis: The McDonald Criteria
EP. 2: Differential Diagnosis of Multiple Sclerosis
EP. 3: MOG-IgG in Multiple Sclerosis
EP. 4: Clinically Isolated Syndrome Versus Multiple Sclerosis
EP. 5: First-Line Therapies for Relapsing Multiple Sclerosis
EP. 6: The Use of Interferon in Multiple Sclerosis
EP. 7: The Use of Glatiramer Acetate in Multiple Sclerosis
EP. 8: Clinical Trials for Cladribine in Multiple Sclerosis
EP. 9: Treating With Cladribine in Multiple Sclerosis
EP. 10: Role of Siponimod in Multiple Sclerosis
EP. 11: Ocrelizumab for the Treatment of Multiple Sclerosis
EP. 12: Role of Ocrelizumab in Europe for Multiple Sclerosis
EP. 13: Role of Diroximel Fumarate in Multiple Sclerosis
EP. 14: Role of Ozanimod in Multiple Sclerosis
EP. 15: Switching Therapies in Multiple Sclerosis
EP. 16: Decision-Making Process for Treating Multiple Sclerosis
EP. 17: The Future of Treating Multiple Sclerosis
Management of Cardiac Amyloidosis
EP. 1: Cardiac Amyloidosis Diagnostic Workup
EP. 2: Hypertrophic Cardiomyopathy Historical Prognosis
EP. 3: AL and ATTR Diagnosis: Echo and Noncardiac Biopsy
EP. 4: When Are Heart Biopsies Warranted?
EP. 5: Technetium Pyrophosphate Scan Benefits
EP. 6: Monoclonal Protein Testing and Wild-Type ATTR
EP. 7: Technetium Pyrophosphate Scan Prior to TAVR
EP. 8: AL and ATTR Survival Metrics
EP. 9: Poor Toleration: AL and ATTR Treatment Modification
EP. 10: Cardioversion and Atrial Fibrillation Ablation
EP. 11: Cardiac Amyloidosis: Pacemakers and Defibrillators
EP. 12: Therapy Selection for Congestive Heart Failure
EP. 13: Available ATTR Selective Stabilizers
EP. 14: Cardiomyopathy Management: NSAID Options
EP. 15: TTR Gene Silencers as Cardiomyopathy Treatment
EP. 16: Developing Agents for Cardiac Amyloidosis Management
Advances in the Treatment of Spinal Muscular Atrophy
EP. 1: Overview of Spinal Muscular Atrophy
EP. 2: Phenotypes of Spinal Muscular Atrophy
EP. 3: Newborn Screening for Spinal Muscular Atrophy
EP. 4: Genetic Testing for Spinal Muscular Atrophy
EP. 5: Motor Testing to Assess Patients With SMA
EP. 6: Involvement of Primary Care Physicians in Diagnosing SMA
EP. 7: Pulmonary Care for Patients With Spinal Muscular Atrophy
EP. 8: GI Complications in Patients With Spinal Muscular Atrophy
EP. 9: Multidisciplinary Approach to Treating SMA
EP. 10: Recent Approval of Zolgensma for SMA
EP. 11: STR1VE Trial of Onasemnogene Abeparvovec for SMA
EP. 12: SPR1NT Trial of Onasemnogene Abeparvovec for SMA
EP. 13: Nusinersen for Treatment of SMA
EP. 14: Nusinersen ENDEAR-SHINE and CHERISH-SHINE for SMA
EP. 15: Nusinersen Phase 2 NURTURE Trial for SMA
EP. 16: Risdiplam in Development for SMA
EP. 17: Clinical Trials for Risdiplam for SMA
EP. 18: Final Thoughts on Treating SMA
Management of Narcolepsy and Excessive Daytime Sleepiness
EP. 1: Overview of Excessive Daytime Sleepiness
EP. 2: Overview of Narcolepsy
EP. 3: Signs and Symptoms of Narcolepsy
EP. 4: Narcolepsy Type 1 and Type 2
EP. 5: Diagnosis of Narcolepsy
EP. 6: Goals of Therapy in Narcolepsy
EP. 7: Nonpharmacologic Therapies for Narcolepsy
EP. 8: Laboratory Testing in Patients with Narcolepsy
EP. 9: Traditional Treatments for Narcolepsy
EP. 10: Pitolisant: Recently FDA Approved for Narcolepsy
EP. 11: Solriamfetol: Recently FDA Approved for Narcolepsy
EP. 12: Deciding Which Drug to Use in Narcolepsy
EP. 13: Insurance Coverage For Drugs to Treat Narcolepsy
EP. 14: Patient Resources Including the Narcolepsy Network
EP. 15: Drugs in Development for Treatment of Narcolepsy
EP. 16: Unmet Needs in the Treatment of Narcolepsy
EP. 17: Advice for Community Physicians Treating Narcolepsy
EP. 18: Referral to a Sleep Specialist to Treat Narcolepsy
EP. 19: Final Thoughts on Treating Narcolepsy